3 most recent filings and news items mentioning KRYS. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/KRYS/news?limit=20"
Pull KRYS filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayKrystal Bio reported $119.2M in VYJUVEK revenue for Q2 2026, showcasing growing commercial traction. Maintaining a $1.1B cash balance, the company is on track for launches in Spain and Italy and advancing multiple registrations.
View filing at SEC.gov →Krystal Biotech reversed previous full-year guidance to reflect substantial contributions to revenue from OCLs, the Antares ZRN-401 combination product will be considered in guidance, and the guidance downgrade materializes following the agreement to acquire VectivBio. The guidan
View filing at SEC.gov →Quince Therapeutics adopted a 1-for-20 reverse stock split effective June 2026 following board and shareholder approval. This corporate restructuring consolidates outstanding shares to potentially bolster the market price per share.
View filing at SEC.gov →